First human patient is injected with 'revolutionary' cancer-killing virus
By Sophie Curtis For Mailonline
17:01 23 May 2022, updated 17:01 23 May 2022 https://www.dailymail.co.uk/sciencetech/article-10846211/First-human-patient-injected-revolutionary-cancer-killing-virus.html
Scientists have injected the first human patient with a new 'cancer-killing virus'
The virus, known as Vaxinia, has been shown to shrink solid tumours in animals
Tests show it reduced the size of colon, lung, breast, and ovarian tumours
It also primed the patient's immune system for immunotherapy treatment
A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors - Full Text View - ClinicalTrials.gov
ClinicalTrials.gov Identifier: NCT05346484
Recruitment Status : Not yet recruiting
First Posted : April 26, 2022
Last Update Posted : April 26, 2022 https://clinicaltrials.gov/ct2/show/NCT05346484
Brief Summary:
This is an open-label, dose-escalation, multi-center phase I study evaluating the safety of CF33-hNIS (hNIS - human sodium iodide symporter) administered via two routes of administration, intratumoral (IT) or intravenous (IV), either as a monotherapy or in combination with pembrolizumab in patients with metastatic or advanced solid tumors.
First human patient is injected with 'revolutionary' cancer-killing virus
By Sophie Curtis For Mailonline
17:01 23 May 2022, updated 17:01 23 May 2022
https://www.dailymail.co.uk/sciencetech/article-10846211/First-human-patient-injected-revolutionary-cancer-killing-virus.html
Scientists have injected the first human patient with a new 'cancer-killing virus'
The virus, known as Vaxinia, has been shown to shrink solid tumours in animals
Tests show it reduced the size of colon, lung, breast, and ovarian tumours
It also primed the patient's immune system for immunotherapy treatment
A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors - Full Text View - ClinicalTrials.gov
ClinicalTrials.gov Identifier: NCT05346484
Recruitment Status : Not yet recruiting
First Posted : April 26, 2022
Last Update Posted : April 26, 2022
https://clinicaltrials.gov/ct2/show/NCT05346484
Brief Summary:
This is an open-label, dose-escalation, multi-center phase I study evaluating the safety of CF33-hNIS (hNIS - human sodium iodide symporter) administered via two routes of administration, intratumoral (IT) or intravenous (IV), either as a monotherapy or in combination with pembrolizumab in patients with metastatic or advanced solid tumors.